Compare Novartis AG (NVS) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Sony Group Corp — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Sony Group Corp trades at $24.05 (market cap $138.06B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Sony Group Corp for 96 Days on average.
| NVS | SONY | |
|---|---|---|
Market Cap | $274.00B | $138.06B |
Volume | 1,852,137 | 3,986,731 |
Sector | Health | Technology |
52-Week High | $168.62 | $30.26 |
52-Week Low | $121.80 | $19.32 |
Typical Hold Time | 82 Days | 96 Days |
Enterprise Value | $315.32B | $135.96B |
Dividend Yield | 3.31% | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Sony trades at $23.95, up 0.42% with neutral technical signals. The company shows strong cash flow generation ($2.32T operating cash flow in 2025) and beat earnings expectations in two of the last three quarters. However, 2026 projections indicate potential challenges with negative net income margin and declining revenue. Analyst sentiment remains positive with 11 buy ratings and no sell recommendations among 16 analysts covering the stock.
Sony presents a mixed investment case with solid entertainment assets and cash flow strength offset by near-term profitability concerns. The stock's reasonable valuation (P/E 19.93, P/S 1.75) and strong analyst support provide upside potential, but investors must monitor execution against 2026 guidance and competitive pressures in entertainment markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
